Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatocellular Cancer
New data from X.Y. Yin et al illuminate research in hepatocellular cancer
May 21st, 2008
In this recently published article, scientists in Guangzhou, People's Republic of China conducted a study "To assess the ability of hepatocellular carcinoma (HCC) patient-derived dendritic cells (DCs) fused with allogeneic HCC cell line to activate autologous lymphocytes to generate specific cytotoxic T lymphocytes (CTL) in vitro. DCs were obtained by culturing adherent peripheral blood mononuclear cells (PBMC) from HCC patients in the presence of 100 mu g/L recombinant human granulocyte/macrophage-colony stimulating factor (rhGM-CSF) and 20 mu g/L interleukin-4 (rhIL-4) for I week in vitro." "DCs were fused with allogeneic HCC cell line HepG2 cells using...
Source: Immunotherapy Weekly (2008-05-21)
|
